- Home
- PCH vs MIRM Comparison
PCH vs MIRM Comparison
Compare PCH & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCH
- MIRM
- Stock Information
- Founded
- PCH 1903
- MIRM 2018
- Country
- PCH United States
- MIRM United States
- Employees
- PCH N/A
- MIRM N/A
- Industry
- PCH Real Estate Investment Trusts
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- PCH Real Estate
- MIRM Health Care
- Exchange
- PCH Nasdaq
- MIRM Nasdaq
- Market Cap
- PCH 3.3B
- MIRM 3.3B
- IPO Year
- PCH N/A
- MIRM 2019
- Fundamental
- Price
- PCH $41.64
- MIRM $74.81
- Analyst Decision
- PCH Strong Buy
- MIRM Strong Buy
- Analyst Count
- PCH 7
- MIRM 9
- Target Price
- PCH $49.86
- MIRM $73.89
- AVG Volume (30 Days)
- PCH 454.8K
- MIRM 746.5K
- Earning Date
- PCH 10-27-2025
- MIRM 11-11-2025
- Dividend Yield
- PCH 4.21%
- MIRM N/A
- EPS Growth
- PCH 15.06
- MIRM N/A
- EPS
- PCH 0.53
- MIRM N/A
- Revenue
- PCH $1,056,523,000.00
- MIRM $429,161,000.00
- Revenue This Year
- PCH $4.42
- MIRM $52.71
- Revenue Next Year
- PCH $3.61
- MIRM $19.71
- P/E Ratio
- PCH $80.71
- MIRM N/A
- Revenue Growth
- PCH N/A
- MIRM 62.33
- 52 Week Low
- PCH $36.82
- MIRM $36.86
- 52 Week High
- PCH $48.12
- MIRM $78.10
- Technical
- Relative Strength Index (RSI)
- PCH 48.33
- MIRM 64.64
- Support Level
- PCH $41.22
- MIRM $73.70
- Resistance Level
- PCH $42.79
- MIRM $77.96
- Average True Range (ATR)
- PCH 1.00
- MIRM 2.44
- MACD
- PCH -0.08
- MIRM -0.52
- Stochastic Oscillator
- PCH 41.22
- MIRM 54.28
About PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.